These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20019088)

  • 21. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.
    Briasoulis E; Kalofonos H; Bafaloukos D; Samantas E; Fountzilas G; Xiros N; Skarlos D; Christodoulou C; Kosmidis P; Pavlidis N
    J Clin Oncol; 2000 Sep; 18(17):3101-7. PubMed ID: 10963638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.
    Hisamatsu T; Mabuchi S; Yoshino K; Fujita M; Enomoto T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2012 May; 22(4):623-9. PubMed ID: 22343974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
    Inal A; Kaplan MA; Kuçukoner M; Urakci Z; Guven M; Nas N; Yunce M; Işikdogan A
    Asian Pac J Cancer Prev; 2012; 13(8):3869-72. PubMed ID: 23098485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature.
    Amela EY; Lauridant-Philippin G; Cousin S; Ryckewaert T; Adenis A; Penel N
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):213-23. PubMed ID: 22503530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized Phase II trial in patients with carcinoma of an unknown primary site.
    Dowell JE; Garrett AM; Shyr Y; Johnson DH; Hande KR
    Cancer; 2001 Feb; 91(3):592-7. PubMed ID: 11169943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Choueiri TK; Mullane S; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Buonerba C; Rozzi A; Matsumoto K; Lee JL; Kitamura H; Kume H; Bellmunt J
    Eur Urol; 2016 Apr; 69(4):634-641. PubMed ID: 26264159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of patients with cancer of unknown primary site.
    Hainsworth JD; Greco FA
    Oncology (Williston Park); 2000 Apr; 14(4):563-74; discussion 574-6, 578-9. PubMed ID: 10826316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
    Hainsworth JD; Spigel DR; Thompson DS; Murphy PB; Lane CM; Waterhouse DM; Naot Y; Greco FA
    Oncologist; 2009 Dec; 14(12):1189-97. PubMed ID: 19965914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
    Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
    Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
    Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma.
    Orita Y; Sugitani I; Matsuura M; Ushijima M; Tsukahara K; Fujimoto Y; Kawabata K
    Surgery; 2010 Mar; 147(3):424-31. PubMed ID: 20176243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tyrosine kinase inhibitor sunitinib therapy is effective in the treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival.
    Ma Y; Zhou W; He S; Xu W; Xiao J
    Int J Cancer; 2016 Sep; 139(6):1423-30. PubMed ID: 27164264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of prognosis for carcinoma of unknown origin in elderly patients.
    Lu HJ; Chen KW; Tzeng CH; Liu JH; Chiou TJ; Yen CC; Chao TC; Teng HW; Chen MH; Liu CY; Wang WS; Chang PM; Yang MH
    Oncology; 2012; 83(1):24-30. PubMed ID: 22722484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets.
    Pavlidis N
    Ann Oncol; 2012 Sep; 23 Suppl 10():x282-5. PubMed ID: 22987978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain metastases in patients with cancer of unknown primary.
    Bartelt S; Lutterbach J
    J Neurooncol; 2003 Sep; 64(3):249-53. PubMed ID: 14558600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
    Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait.
    Huey RW; Makawita S; Xiao L; Matamoros A; Estrella JS; Overman MJ; Varadhachary GR; Raghav K
    BMC Cancer; 2019 Oct; 19(1):965. PubMed ID: 31623602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of prognostic factors in 68 patients with cancer of unknown primary site].
    Kou XG; Liang DL; Zhang QQ; Li XR; Zhao YZ; Gu JF; Lu P
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):783-6. PubMed ID: 22335913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan.
    Abe T; Ishizaki J; Kikuchi H; Minami K; Matsumoto R; Harabayashi T; Sazawa A; Mochizuki T; Chiba S; Akino T; Murakumo M; Miyajima N; Tsuchiya K; Maruyama S; Murai S; Shinohara N
    Urol Oncol; 2017 Feb; 35(2):38.e1-38.e8. PubMed ID: 27693091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.